Clinical trials: Wet Macular Degeneration
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients
Primary objective: To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients.
- Trial name
- NCT07728981
- Testing
- Aflibercept 8mg
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Eye Hospital
Macular Degeneration
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary…
- Trial name
- NCT00090623
- Testing
- rhuFab V2 (ranibizumab)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Genentech, Inc.
Macular Degeneration, Wet Macular Degeneration
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
- Trial name
- EAGLE (NCT02689518)
- Testing
- Intravitreal aflibercept injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Wet Age-Related Macular Degeneration
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with wet Age Related Macular Degeneration.
- Trial name
- NCT01086761
- Testing
- MP0112
- Where
- 8 sites in Czechia, France and 1 more
- Volunteers
- 32 people
- Sponsor
- Allergan
Macular Degeneration
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to…
- Trial name
- COBALT (NCT00499590)
- Testing
- bevasiranib, ranibizumab
- Where
- 60 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- OPKO Health, Inc.
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- TORRONTES (NCT07496567)
- Testing
- Tiespectus, Aflibercept
- Where
- 71 sites in United States, Brazil and 7 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Age-Related Macular Degeneration
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in patients with wet AMD when…
- Trial name
- NCT00321997
- Testing
- Pegaptanib sodium
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Vision Improvement for Patients With Age-Related Macular Degeneration
The purpose of this study is to determine whether the Optimal Acuity Clear-K® Low Vision Aid System provides a safe and effective treatment to improve vision for patients with age-related macular degeneration.
- Trial name
- AMD (NCT04268836)
- Testing
- Optimal Acuity Clear-K® Low Vision Aid System treatment
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Age Related Macular Degeneration
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
The purpose of the study is to provide efficacy and safety data for monthly ranibizumab 0.5 mg intravitreal injections in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- EXTEND II (NCT00826371)
- Testing
- ranibizumab 0.5 mg
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration
Efficacy and Safety of RC28-E Versus Aflibercept
This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients…
- Trial name
- NCT05727397
- Testing
- RC28-E, Aflibercept
- Where
- China
- Volunteers
- 432 people
- Sponsor
- RemeGen Co., Ltd.
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the efficacy and safety of SMZ1 tablets in combination with Ranibizumab compared with placebo in combination with Ranibizumab in subjects with neovascular (wet) age-related macular…
- Trial name
- NCT07695207
- Testing
- SMZ1
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- SANGMYUNG innovation
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Macular Degeneration
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31…
- Trial name
- REVIEW (NCT01933152)
- Testing
- Ranibizumab
- Where
- Portugal
- Volunteers
- 137 people
- Sponsor
- Bayer
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.
- Trial name
- NCT03249740
- Testing
- GB-102, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Graybug Vision
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
Wet Macular Degeneration
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated
- Trial name
- RAINBOW (NCT02279537)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 593 people
- Sponsor
- Bayer